NCT05031949View on ClinicalTrials.gov

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 30, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Combinational ImmunotherapyHepatocellular Carcinoma Non-ResectableHyperbaric Oxygen Therapy
Interventions
COMBINATION_PRODUCT

hyperbaric oxygen therapy plus Camrelizumab

Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody

Trial Locations (1)

430030

RECRUITING

Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Zhang Bi Xiang, MD

OTHER